Science6 months ago
Mavacamten and Aficamten Show Promise in Phase 3 Trials for HCM
The results from pivotal Phase 3 trials for cardiac myosin inhibitors, specifically mavacamten and aficamten, have demonstrated significant clinical benefits for patients with hypertrophic cardiomyopathy (HCM)....
